公开(公告)号：US20130296190A1

公开(公告)日：2013-11-07

申请号：US13990495

申请日：2011-11-30

申请人： Yafeng Dong ,  Carl Weiner

发明人： Yafeng Dong ,  Carl Weiner

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2800/368

摘要： A nucleic acid normalization kit can include a nucleic acid having a normalization sequence including or complementary to one or more of SEQ ID NOs: 1-4 and 301-303 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid normalization protocol. The normalization kit can be used in a method of identifying a pregnancy normalization nucleic acid sequence. A nucleic acid diagnostic kit for diagnosing susceptibility to preterm birth (PTB) can include a nucleic acid having a CFP RNA PTB biomarker sequence including or complementary to one or more of SEQ ID NOs: 5-300 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid diagnostic protocol for diagnosing susceptibility to PTB. The diagnostic kit can be used in a method for predicting susceptibility of a pregnant woman to preterm birth (PTB).

摘要翻译： 核酸标准化试剂盒可以包括具有包括或互补于SEQ ID NO：1-4和301-303中的一个或多个或其独特片段的归一化序列的核酸，所述核酸以足以用于 核酸标准化方案。 归一化试剂盒可用于鉴定怀孕归一化核酸序列的方法。 用于诊断早产易感性的核酸诊断试剂盒可以包括具有包含SEQ ID NO：5-300或其独特片段中的一个或多个的CFP RNA PTB生物标志物序列的核酸，其核酸是 存在足以用于诊断PTB易感性的核酸诊断方案中的量。 诊断试剂盒可用于预测孕妇对早产（PTB）的易感性的方法。

公开(公告)号：US20130274123A1

公开(公告)日：2013-10-17

申请号：US13792844

申请日：2013-03-11

申请人： DIABETOMICS, LLC

发明人： Srinivasa R. Nagalla

IPC分类号： G01N33/68 ,  G01N33/76

CPC分类号： G01N33/689 ,  G01N33/74 ,  G01N33/76 ,  G01N2333/471 ,  G01N2333/78 ,  G01N2800/042 ,  G01N2800/368 ,  G01N2800/60

摘要： Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof.

公开(公告)号：US08492104B2

公开(公告)日：2013-07-23

申请号：US13454276

申请日：2012-04-24

申请人： Manish S. Patankar ,  Joseph P. Connor ,  Jennifer A. Belisle

发明人： Manish S. Patankar ,  Joseph P. Connor ,  Jennifer A. Belisle

IPC分类号： G01N33/53

CPC分类号： G01N33/57449 ,  G01N33/56972 ,  G01N33/689 ,  G01N2800/368

摘要： The present invention provides methods and kits related to a prognostic, and, in certain embodiments, diagnostic indicator for ovarian cancer which comprises measuring the level of MUC16 bound to immune cells. The level of MUC16 bound to immune cells can by itself be an indicator of disease regression or recurrence, or this indicator can be used in conjunction with assays for serum CA125 and other diagnostic markers. The invention further provides methods and kits related to the detection of ovarian cancer by measuring levels of Siglec-9 expression on immune cells. As well, related methodologies are provided for the detection of preeclampsia in pregnant human subjects.

摘要翻译： 本发明提供了与预后相关的方法和试剂盒，在某些实施方案中，涉及卵巢癌的诊断指标，其包括测量与免疫细胞结合的MUC16的水平。 与免疫细胞结合的MUC16的水平本身可以是疾病退化或复发的指标，或者该指标可以与血清CA125和其他诊断标记物的检测结合使用。 本发明还通过测量免疫细胞上的Siglec-9表达水平来进一步提供与卵巢癌检测有关的方法和试剂盒。 同样，提供相关方法用于检测怀孕人类受试者的先兆子痫。

公开(公告)号：US08486690B2

公开(公告)日：2013-07-16

申请号：US13157508

申请日：2011-06-10

申请人： David Hugh Burns

发明人： David Hugh Burns

IPC分类号： C12M1/36

CPC分类号： G01N21/31 ,  G01N21/359 ,  G01N21/65 ,  G01N33/5091 ,  G01N33/689 ,  G01N2021/6482 ,  G01N2021/651 ,  G01N2201/1293 ,  G01N2800/367 ,  G01N2800/368 ,  G01R33/465 ,  G06F19/18

摘要： The present invention relates to a method for determining the ideal time for and outcome of reproductive health procedures including in vitro fertilization by establishing a correlation between the successful outcome of said procedure and the spectra of a body fluid obtained using a chosen analytical modality for a population of patients, acquiring for a patient a spectrum of the body fluid of the patient using said chosen modality.

摘要翻译： 本发明涉及一种用于确定生殖健康程序的理想时间和结果的方法，包括体外受精，通过建立所述过程的成功结果与使用所选择的分析模式获得的体液的体液的光谱之间的相关性 的患者，使用所选择的方式向患者获得患者体液的频谱。

公开(公告)号：US20130071861A1

公开(公告)日：2013-03-21

申请号：US13551089

申请日：2012-07-17

申请人： Murugan R. Pandian ,  Julie Y. Yu

发明人： Murugan R. Pandian ,  Julie Y. Yu

IPC分类号： G01N33/577 ,  G01N21/76

CPC分类号： G01N33/57476 ,  G01N33/689 ,  G01N2800/368 ,  G01N2800/387 ,  Y10S436/811

摘要： Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.

公开(公告)号：US20130045889A1

公开(公告)日：2013-02-21

申请号：US13640914

申请日：2011-04-13

申请人： Koen Kas

发明人： Koen Kas

IPC分类号： G01N27/62 ,  G01N21/76 ,  C40B40/10 ,  C40B30/04 ,  G01N33/566 ,  C12M1/34 ,  C40B60/12 ,  G01N21/64 ,  C40B40/04

CPC分类号： G01N33/689 ,  G01N2800/368 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56

摘要： The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.

摘要翻译： 该申请公开了用于妊娠高血压疾病，特别是先兆子痫的新生物标志物; 基于测量所述生物标志物来诊断，预测，预后和/或监测所述疾病的方法; 以及用于测量所述生物标志物和/或执行所述方法的试剂盒和装置。

公开(公告)号：US20130017958A1

公开(公告)日：2013-01-17

申请号：US13502498

申请日：2010-10-26

申请人： Marcus Benz ,  Wera Hofmann ,  Thomas Pohl ,  Christoph Von Kalle

发明人： Marcus Benz ,  Wera Hofmann ,  Thomas Pohl ,  Christoph Von Kalle

IPC分类号： C40B20/00 ,  C40B60/06

CPC分类号： G01N33/574 ,  C12Q1/6806 ,  C12Q1/6851 ,  G01N2800/368 ,  G01N2800/385 ,  G06F19/22 ,  C12Q2525/107 ,  C12Q2525/121 ,  C12Q2537/157 ,  C12Q2545/101

摘要： The invention relates to a prenatal diagnostic method for the determination of a fetal chromosomal aneuploidy in a biological sample obtained from a pregnant woman, which method comprises enrichment and quantification of selected cell-free deoxyribonucleic acid sequences showing consensus nucleosome binding regions.

摘要翻译： 本发明涉及一种用于测定从孕妇获得的生物样品中胎儿染色体非整倍性的产前诊断方法，该方法包括浓缩和定量显示共有核小体结合区域的所选择的无细胞脱氧核糖核酸序列。

公开(公告)号：US20120264140A1

公开(公告)日：2012-10-18

申请号：US13454276

申请日：2012-04-24

申请人： Manish S. Patankar ,  Joseph P. Connor ,  Jennifer A. Belisle

发明人： Manish S. Patankar ,  Joseph P. Connor ,  Jennifer A. Belisle

IPC分类号： G01N33/574 ,  G01N33/566

CPC分类号： G01N33/57449 ,  G01N33/56972 ,  G01N33/689 ,  G01N2800/368

摘要： The present invention provides methods and kits related to a prognostic, and, in certain embodiments, diagnostic indicator for ovarian cancer which comprises measuring the level of MUC16 bound to immune cells. The level of MUC16 bound to immune cells can by itself be an indicator of disease regression or recurrence, or this indicator can be used in conjunction with assays for serum CA125 and other diagnostic markers. The invention further provides methods and kits related to the detection of ovarian cancer by measuring levels of Siglec-9 expression on immune cells. As well, related methodologies are provided for the detection of preeclampsia in pregnant human subjects.

摘要翻译： 本发明提供了与预后相关的方法和试剂盒，在某些实施方案中，涉及卵巢癌的诊断指标，其包括测量与免疫细胞结合的MUC16的水平。 与免疫细胞结合的MUC16的水平本身可以是疾病退化或复发的指标，或者该指标可以与血清CA125和其他诊断标记物的检测结合使用。 本发明还通过测量免疫细胞上的Siglec-9表达水平来进一步提供与卵巢癌检测有关的方法和试剂盒。 同样，提供相关方法用于检测怀孕人类受试者的先兆子痫。

公开(公告)号：US20120214685A1

公开(公告)日：2012-08-23

申请号：US13397442

申请日：2012-02-15

申请人： David W. Speicher ,  Kurt T. Barnhart ,  Lynn A. Beer

发明人： David W. Speicher ,  Kurt T. Barnhart ,  Lynn A. Beer

IPC分类号： C40B30/04 ,  C40B40/06 ,  C40B40/10 ,  C07K2/00 ,  G01N33/573 ,  C07K16/18 ,  G01N33/566 ,  C12Q1/68 ,  C40B30/10 ,  C07K16/40 ,  C07H21/00 ,  C07K14/00

CPC分类号： G01N33/6893 ,  C07K14/705 ,  G01N33/76 ,  G01N2333/471 ,  G01N2333/70503 ,  G01N2560/00 ,  G01N2800/368 ,  G01N2800/60

摘要： Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.

摘要翻译： 提供了通过检测ISM2，ADAM12，PST1，PSG7，PST11，PSG9，PSG2和其中鉴定的其他基因（包括其组合）的表达变化来诊断哺乳动物受试者异位妊娠的方法和组合物。 在受试者的生物流体中检测到的选择的基因，基因转录物或蛋白质/肽表达产物或通过其组合形成的特征或特征可以与相应的基因，蛋白质或轮廓比较， 子宫内正常怀孕。 检测受试者的基因谱或蛋白质表达特征的特征变化与异位妊娠的诊断相关。 用于这种诊断的各种组合物包括能够检测这些靶标的表达或翻译变化的PCR引物 - 探针组或标记或固定的配体。

公开(公告)号：US20120149041A1

公开(公告)日：2012-06-14

申请号：US13390748

申请日：2010-08-19

申请人： Steven W Graves ,  Sean Michael Esplin

发明人： Steven W Graves ,  Sean Michael Esplin

IPC分类号： G01N33/53

CPC分类号： G01N33/689 ,  G01N2800/368

摘要： Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying a first biomarker and a second biomarker associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth.

摘要翻译： 这里描述的是评估孕妇早产风险的方法。 所述方法涉及检测和定量来自受试者的生物样品中的与早产相关的第一生物标志物和第二生物标志物。 本文还描述了可用于预测早产风险的分离的生物标志物和试剂盒。